Verve Therapeutics Investor Relations Material
Latest events
Study Update
Verve Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Verve Therapeutics Inc
Access all reports
Verve Therapeutics Inc., founded in 2018, is a genetic medicines company focused on developing gene editing treatments for cardiovascular diseases. The company's flagship product, VERVE-101, is a single-course gene editing treatment designed to permanently inactivate the PCSK9 gene in the liver, with an aim to address cardiovascular conditions effectively. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
VERV
Country
🇺🇸 United States